First Units on Sale Today at Newburgh Dispensary with Availability Tomorrow at Carle Place, Forest Hills, and Plattsburgh Locations
With Enough Product to Supply Wholesale Partners by Month’s End
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today announced that its initial batches of New York whole flower have cleared testing by third party labs and that sales of three initial strains will begin this afternoon in Company’s Newburgh location and tomorrow afternoon in Curaleaf’s Carle Place, Forest Hills, and Plattsburgh dispensaries.
“Our patients have been waiting a long time for this day and we couldn’t be happier to be able to deliver whole flower product to all four of our New York locations in the next day or so and to the majority of our wholesale partners within the month,” said Joe Bayern, CEO of Curaleaf. “Fortunately, we have been preparing for this moment and we are more than ready with plenty of product for all our New York locations. We are grateful to Governor Hochul and the OCM for moving this forward so quickly, and we look forward to robust sales and happy customers. We appreciate the patience and loyalty of all our patients as we worked toward this milestone.”
Prior to this month, cannabis was only available to New York patients in ground form, a source of frustration for many patients who prefer the plant’s medicinal applications in its purest and most natural format.
Curaleaf whole flower will also be available to the majority of the Company’s wholesale partners in the state by the end of the month, ensuring that the Company maintains its position as the New York market leader and its product will be available throughout the state.